A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10282819" target="_blank" >RIV/00216208:11110/14:10282819 - isvavai.cz</a>
Alternative codes found
RIV/00023001:_____/14:00059165 RIV/00064165:_____/14:10282819
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1316222" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1316222</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1316222" target="_blank" >10.1056/NEJMoa1316222</a>
Alternative languages
Result language
angličtina
Original language name
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Original language description
Evolocumab significantly reduced low-density lipoprotein (LDL) cholesterol. Patients were started on background lipid-lowering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period of 4 to 12 weeks. Among the 901 patients included in the primary analysis, the overall least-squares mean (+/- SE) reduction in LDL cholesterol from baseline in theevolocumab group, taking into account the change in the placebo group, was 57.0 +/- 2.1% (P<0.001). The mean reduction was 55.7 +/- 4.2% among patients who underwent background therapy with diet alone, 61.6 +/- 2.6% among those who received 10 mg of atorvastatin, 56.8 +/- 5.3% among those who received 80 mg of atorvastatin, and 48.5 +/- 5.2% among those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all comparisons).At 52 weeks, evolocumab added
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
370
Issue of the periodical within the volume
19
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
1809-1819
UT code for WoS article
000335997900038
EID of the result in the Scopus database
—